Uncontrolled, Open-label, Non-randomized, Phase I Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Regorafenib in Chinese Patients (China Mainland) With Advanced, Refractory Solid Tumors)
Phase of Trial: Phase I
Latest Information Update: 03 Aug 2016
At a glance
- Drugs Regorafenib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Bayer
- 29 Jul 2016 Status changed from active, no longer recruiting to completed.
- 10 Jun 2016 Planned End Date changed from 1 Oct 2016 to 1 Jun 2016.
- 26 Feb 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Mar 2016, according to ClinicalTrials.gov record.